ClinicalTrials.gg
RecruitingNCT04388930Updated Dec 14, 2023

The Microbiota in Kidney Donation and Transplantation

An observational study in Kidney Diseases, Kidney Transplant Failure and Rejection and Urinary Tract Infections, sponsored by Royal Free Hospital NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by Royal Free Hospital NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Kidney Diseases with a site in United Kingdom — 13 open to participants now, 25 under way, 10 of them phase 3. Kidney Diseases · United Kingdom.

Planned enrollment
7th of 16
130 · median 122
Started
2020
with 3 others
Observational
16 of 63
6 open now
Primary completion
2025-06
later than 5 of 24 live
Registered
35th of 63
by date

Among the 63 studies in Kidney Diseases with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2020, is one of 16 observational ones, reaches primary completion later than 5 of the 24 other live ones, and was the 35th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

13 of the 63 studies in Kidney Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Kidney Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

The human gastrointestinal tract harbours \~40 trillion microbial cells, far outnumbering the cell number, and therefore the genetic content of its host. How this genetically diverse bacterial (collectively referred as 'microbiota') co-resident modulates host homeostasis is largely unknown. We are increasing gaining a better understanding how the microbes modulate mucosal and systemic metabolic/immune and organ systems including the kidney, heart and the brain. Therapeutic targeting of the gastrointestinal (GI) microbiota may help improve clinical outcomes in conditions as diverse as arthritis, cardiovascular disease, and cancer. In contrast to other organ systems, studies investigating the role of the microbiota in modulating clinical outcomes in renal transplantation lags behind.

The aim of the study is to examine (a) how alterations in the urinary and GI microbiota and associated metabolites impact on host immunity after renal transplantation, and (b) whether such changes are correlated with post-transplant complications, such as rejection, development of de novo donor specific antibodies, metabolic complications (e.g post-transplant diabetes) and infections. Participants will be followed before and up to twelve months post-transplantation, and, longitudinal microbial data will be correlated with in-depth immune phenotyping and clinical end-points to define the impact that changes in urinary and GI microbial ecology have on kidney transplant outcomes.

03

Conditions studied

  • Kidney Diseases
  • Kidney Transplant Failure and Rejection
  • Urinary Tract Infections
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Renal transplant live-donors and recipients of live-donor and cadaveric renal transplants

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult (≥18 years old) undergoing living donor nephrectomy or kidney transplantation. Patients willing to provide samples including Urine, Blood, Faecal samples.

    1. Participant able to give
    2. All patients will be at least 18 years old
    3. Patients will either be a live renal transplant donor or a renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible renal transplant.
    4. Patients attending hospital clinics at participating centre for routine clinical follow -up.
    5. Patients willing to comply with study procedures and willing to provide blood, faecal and urine samples.

Exclusion criteria

Exclusion Criteria:

  1. Patients under the age of 18 years
  2. Patients unable to give
  3. Patients not able to comply with study procedures or follow-up visits
  4. Patients that are not a live renal donor or that are not on the waiting list to have or have not had an ABO blood group compatible renal transplant and are not attending hospital outpatient clinics at participating study centres for routine clinical follow-up.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Kidney transplant live-donor

    Participants that will be a planned live renal transplant donor

    Other: Pre-operative assessment - blood, urine, & faecal sample · Other: Post-operative day 3 assessment - blood, urine, & faecal sample · Other: Post-operative week 4-6 assessment - blood, urine, & faecal sample · Other: Post-operative 3 month assessment - blood, urine, & faecal sample · Other: Pre-operative 6 month assessment - blood, urine, & faecal sample · Other: Post-operative month 12 recipient assessment - blood, urine, & faecal sample

  • Kidney transplant recipient

    Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant

    Other: Pre-operative assessment - blood, urine, & faecal sample · Other: Post-operative week 4-6 assessment - blood, urine, & faecal sample · Other: Post-operative 3 month assessment - blood, urine, & faecal sample · Other: Pre-operative 6 month assessment - blood, urine, & faecal sample · Other: Post-operative month 12 recipient assessment - blood, urine, & faecal sample

Interventions

  • OtherPre-operative assessment - blood, urine, & faecal sample

    Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing

  • OtherPost-operative day 3 assessment - blood, urine, & faecal sample

    Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.

  • OtherPost-operative week 4-6 assessment - blood, urine, & faecal sample

    Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.

  • OtherPost-operative 3 month assessment - blood, urine, & faecal sample

    Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.

  • OtherPre-operative 6 month assessment - blood, urine, & faecal sample

    Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.

  • OtherPost-operative month 12 recipient assessment - blood, urine, & faecal sample

    Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.

06

What researchers measure

Primary outcomes

  1. Change in gastrointestinal and urinary microbiota composition and diversity

    To understand the overall impact of transplantation on changes to the urinary and GI microbiota, the relative abundance of bacterial taxa will be evaluated using 16S rRNA gene sequencing methodologies. Alpha and Beta diversity indices will be determined from urine samples and faecal samples before and after live-donation and transplantation.

    Time frame: 1 year

  2. Correlation of change in gastrointestinal and urinary microbiota diversity with post-transplantation outcomes.

    Incidence of renal graft dysfunction will be determined by the Modification of Diet in Renal Disease (MDRD)-derived estimated Glomerular Filtration Rate (eGFR) at 12 months. Graft survival time - date of transplantation to date of irreversible graft failure signified by return to dialysis (or re-transplantation, whichever is earlier) or the date of last follow-up during the period when the transplant was still functioning. In the event of death with a functioning graft, the follow-up period will be censored at the date of death.

    Time frame: 1 year

Secondary outcomes

  1. Change in frequency of conventional and regulatory immune phenotypes and correlation with clinical outcome and microbial diversity changes

    A panel of validated immune monitoring assays (including multi-colour flow cytometry, intracellular cytokine staining, enzyme-linked immune absorbent spot \[ELISpot\], enzyme-linked immunosorbent assay \[ELISA\] and transcriptional analysis) will be used to analyse immunological parameters in patient samples.

    Time frame: 1 year

  2. Change in microbial-associated metabolite profile and correlation with clinical outcomes and/or microbial diversity changes

    A combination of 1H nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography-mass spectrometry will be used to measure the metabolic phenotype of urine and faecal samples from transplant donors and recipients (pre-operatively and up to 12 months after surgery).

    Time frame: 1 year

  3. Incidence of renal graft dysfunction as determined by the MDRD-derived estimated Glomerular Filtration Rate (eGFR).

    A significant deterioration in graft dysfunction is defined as the percent of patients exhibiting an eGFR \<45 mL/min/1.73m2 at month 12 or a decrease in eGFR ≥10 mL/min/1.73m2 from month 3 to month 12 after transplantation.

    Time frame: 1 year

  4. The proportion of patients reaching a defined CKD stage at up to 5 years after transplantation.

    Defined by the kidney disease outcomes quality initiative for CKD stages, with eGFR \<30 mL/min/1.73m2 considered to be advanced renal dysfunction.

    Time frame: 5 years

  5. Incidence of biopsy proven acute or chronic cellular or humoral rejection up to 5 years after transplantation as per Banff classification

    Revised Banff 2017 classification of antibody-mediated rejection and T cell-mediated rejection in renal allografts.

    Time frame: 5 years

  6. Incidence of post-donation and post-transplant bacterial or viral infections up to 5 years after surgery

    Infectious complications will include, but not be limited to, urinary tract infections (defined as a positive urine culture \[\>50,000 CFUs/ml\] from mid-stream urine, and categorised as asymptomatic bacteriuria \[no symptoms\], cystitis \[lower urinary tract symptoms without systemic features\] or pyelonephritis \[systemic features, graft dysfunction, CRP\>50\]), BK viraemia, cytomegalovirus (CMV) viraemia, and respiratory tract (RV) infections.

    Time frame: 5 years

  7. Patient and graft survival rates up to 5 years after transplantation.

    Graft survival time will be calculated from the date of transplantation to the date of irreversible graft failure signified by return to dialysis (or re-transplantation, whichever is earlier) or the date of last follow-up during the period when the transplant was still functioning. In the event of death with a functioning graft, the follow-up period will be censored at the date of death.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Royal Free London NHS Trust
    London, NW3 2QG, United Kingdom
    Recruiting
    • Reza Motallebzadeh, PhD FRCS · Contactr.motallebzadeh@ucl.ac.uk
    • Amanda Bidle · Contactrf.sponsoredresearch@nhs.net · 00442077940500
    • Alan Salama, PhD FRCP · Principal investigator
    • Mark Harber, FRCP · Principal investigator
    • Anne Pesenacker, PhD · Principal investigator
    • Mona Bajaj-Elliott, PhD · Principal investigator
    • Jennifer Rohn, PhD · Principal investigator
    • Maria De Iorio, PhD · Principal investigator
    • Kevin Bryson, PhD · Principal investigator
    • Gurpeet Badhan · Sub investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Jun 2025, 63 months after the start.

Of 100 non-industry observational studies under Kidney Diseases, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 33. This study's planned 63 months is close to that.

Counting every sponsor, half of 117 studies reached it within 59 months; a quarter within 31 and three quarters within 118.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2020
First posted
May 14, 2020
StartActual
Mar 1, 2020
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04388930
Lead sponsor
Royal Free Hospital NHS Foundation Trust
Responsible party
Sponsor
First posted
May 14, 2020
Start date
Mar 1, 2020
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Dec 14, 2023

Study contacts

Reza Motallebzadeh
Contact
r.motallebzadeh@ucl.ac.uk
020 7794 0500
Research and Development Manager
study chair · Sponsor GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion